OGEN - Oragenics, Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.0100 |
| Open | 2.9200 |
| Bid | 2.8800 x 3200 |
| Ask | 3.5900 x 1000 |
| Day's Range | 2.8800 - 3.0500 |
| 52 Week Range | 2.6000 - 24.0000 |
| Volume | |
| Avg. Volume | 15,864 |
| Market Cap | 6.155M |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.2900 |
| Earnings Date | Jul 27, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.00 |
Fair Value
Related Research
Business WireOragenics to Participate in the World Vaccine Congress Washington
TAMPA, Fla., March 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.
Business WireOragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
TAMPA, Fla., March 14, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics. Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infe
Business WireOragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
TAMPA, Fla., March 08, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies.
BenzingaOragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact
Oragenics Inc (NYSE: OGEN) entered into an exclusive global license agreement with Inspirevax Inc for its novel intranasal mucosal adjuvant, BDX301, to develop NT-CoV2-1, Oragenics' lead intranasal COVID-19 vaccine candidate. Under the exclusive licensing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax's BDX301 intranasal mucosal adjuvant. The companies will form a Joint Development Committee (JDC) to oversee the development efforts collaboratively. Oragenics will m
Business WireOragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
TAMPA, Fla., March 01, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
Business WireOragenics, Inc. Regains Compliance with NYSE American
TAMPA, Fla., February 03, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American’s continued listing standards.
InvestorPlace7 Short-Squeeze Stocks to Buy Before They Soar
As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white sharks. As loathsome and fearsome as these creatures may be, they eliminate weak or sick animals, thus benefitting the broader ecology. Similarly, bearish traders identify publicly traded enterprises that supposedly have no business comma
Business WireOragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
TAMPA, Fla., December 23, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the "Board") on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’s authorized shares of common stock (the "Reverse St
Business WireOragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
TAMPA, Fla., December 22, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate. Oragenics believes the findings of the final toxicology report, including a full h
Business WireOragenics, Inc. Receives NYSE American Notice
TAMPA, Fla., December 20, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice (the "Notice") on December 19, 2022 from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").
Business WireOragenics, Inc. Announces New Chair
TAMPA, Fla., December 19, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011. Dr. Telling will remain on the Board as an independent director and a
Business WireOragenics to Participate in the 2022 BioFlorida Annual Conference
TAMPA, Fla., October 24, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.
Business WireOragenics Issues Letter to Shareholders
TAMPA, Fla., September 30, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy.
Business WireOragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
TAMPA, Fla., August 24, 2022--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
Business WireOragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
TAMPA, Fla., June 23, 2022--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
Business WireOragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
TAMPA, Fla., June 14, 2022--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports